# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Adam Maeder initiates coverage on Abbott Laboratories (NYSE:ABT) with a Overweight rating and announce...
Investors are anticipating the first cut to the federal funds rate in over four years at the September FOMC meeting. The market...
Abbott recalls some FreeStyle Libre 3 sensors due to incorrect glucose readings, risking severe health issues.
Designed for people interested in improving their overall health and wellnessProvides real-time glucose data and personal coach...
The U.S. FDA granted Abbott Breakthrough Device designation to explore deep brain stimulation (DBS) for treatment-resistant dep...
Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Qu...
DexCom's Stelo Glucose Biosensor System, the first over-the-counter continuous glucose monitor, is now available without a ...